CO-1024

CO-1024 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Corellia AI, a subsidiary of Champions Oncology. The therapeutic is designed to treat solid tumors with high unmet medical needs, specifically targeting non-small cell lung cancer (NSCLC), colorectal cancer, gastric cancer, and pancreatic cancer. While the specific molecular target of the antibody component has not been publicly disclosed, CO-1024 is part of Corellia AI's platform that utilizes AI-enabled workflows and patient-derived xenograft (PDX) models for discovery. The drug likely employs the company's Coromip technology, which uses the dual PI3K/mTOR inhibitor omipalisib as a cytotoxic payload to target and eliminate cancer cells, particularly in patients who do not achieve durable responses with current immune therapies.